Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt No Debt
AFFY's Cash to Debt is ranked higher than
89% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. AFFY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AFFY' s 10-Year Cash to Debt Range
Min: 8.82  Med: 9999.00 Max: 13531.29
Current: No Debt
8.82
13531.29
Equity to Asset -0.19
AFFY's Equity to Asset is ranked lower than
94% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AFFY: -0.19 )
Ranked among companies with meaningful Equity to Asset only.
AFFY' s 10-Year Equity to Asset Range
Min: -3.14  Med: 0.07 Max: 0.64
Current: -0.19
-3.14
0.64
F-Score: 2
Z-Score: -111.65
M-Score: 25.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -12128.57
AFFY's Operating margin (%) is ranked lower than
94% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. AFFY: -12128.57 )
Ranked among companies with meaningful Operating margin (%) only.
AFFY' s 10-Year Operating margin (%) Range
Min: -45958.11  Med: -128.68 Max: -12.84
Current: -12128.57
-45958.11
-12.84
Net-margin (%) 7300.00
AFFY's Net-margin (%) is ranked higher than
100% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. AFFY: 7300.00 )
Ranked among companies with meaningful Net-margin (%) only.
AFFY' s 10-Year Net-margin (%) Range
Min: -44021.62  Med: -270.20 Max: -12.51
Current: 7300
-44021.62
-12.51
ROE (%) 134.22
AFFY's ROE (%) is ranked higher than
99% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. AFFY: 134.22 )
Ranked among companies with meaningful ROE (%) only.
AFFY' s 10-Year ROE (%) Range
Min: -3061.28  Med: -193.70 Max: -20.19
Current: 134.22
-3061.28
-20.19
ROA (%) 7.32
AFFY's ROA (%) is ranked higher than
86% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. AFFY: 7.32 )
Ranked among companies with meaningful ROA (%) only.
AFFY' s 10-Year ROA (%) Range
Min: -154.34  Med: -46.50 Max: -8.21
Current: 7.32
-154.34
-8.21
ROC (Joel Greenblatt) (%) 308.55
AFFY's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. AFFY: 308.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AFFY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4200.95  Med: -1489.10 Max: -294.87
Current: 308.55
-4200.95
-294.87
Revenue Growth (3Y)(%) -79.40
AFFY's Revenue Growth (3Y)(%) is ranked lower than
88% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AFFY: -79.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AFFY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -11.95 Max: 187
Current: -79.4
0
187
EBITDA Growth (3Y)(%) -7.50
AFFY's EBITDA Growth (3Y)(%) is ranked lower than
54% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. AFFY: -7.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AFFY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -36.90 Max: 25
Current: -7.5
0
25
EPS Growth (3Y)(%) -11.90
AFFY's EPS Growth (3Y)(%) is ranked lower than
56% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. AFFY: -11.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AFFY' s 10-Year EPS Growth (3Y)(%) Range
Min: -65.5  Med: -31.60 Max: 17.4
Current: -11.9
-65.5
17.4
» AFFY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

AFFY Guru Trades in

AFFY Guru Trades in

AFFY Guru Trades in

Q2 2013

AFFY Guru Trades in Q2 2013

Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AFFY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 72.23
AFFY's P/S is ranked higher than
85% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. AFFY: 72.23 )
Ranked among companies with meaningful P/S only.
AFFY' s 10-Year P/S Range
Min: 0.31  Med: 3.65 Max: 26
Current: 72.23
0.31
26
EV-to-EBIT 0.17
AFFY's EV-to-EBIT is ranked higher than
99% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. AFFY: 0.17 )
Ranked among companies with meaningful EV-to-EBIT only.
AFFY' s 10-Year EV-to-EBIT Range
Min: -12.9  Med: -1.60 Max: 3.5
Current: 0.17
-12.9
3.5
Current Ratio 0.71
AFFY's Current Ratio is ranked lower than
90% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. AFFY: 0.71 )
Ranked among companies with meaningful Current Ratio only.
AFFY' s 10-Year Current Ratio Range
Min: 0.71  Med: 2.80 Max: 20.06
Current: 0.71
0.71
20.06
Quick Ratio 0.71
AFFY's Quick Ratio is ranked lower than
88% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. AFFY: 0.71 )
Ranked among companies with meaningful Quick Ratio only.
AFFY' s 10-Year Quick Ratio Range
Min: 0.71  Med: 2.80 Max: 20.06
Current: 0.71
0.71
20.06

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.60
AFFY's Price/Median PS Value is ranked higher than
79% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. AFFY: 0.60 )
Ranked among companies with meaningful Price/Median PS Value only.
AFFY' s 10-Year Price/Median PS Value Range
Min: 0.4  Med: 1.24 Max: 5.2
Current: 0.6
0.4
5.2
Earnings Yield (Greenblatt) (%) 544.07
AFFY's Earnings Yield (Greenblatt) (%) is ranked higher than
100% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. AFFY: 544.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AFFY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 28.4  Med: 292.05 Max: 87233.3
Current: 544.07
28.4
87233.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:A5Y.Germany,
Affymax Inc was incorporated in Delaware in July 2001. The Company is a biopharmaceutical company in the process of restructuring operations. In March 2012, the U.S. Food and Drug Administration, or FDA, approved the Company's first and only product, OMONTYS or peginesatide Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S. In March 2013, Company implemented plans to restructure its operations in order to reduce operating costs and focus on the OMONTYS safety and other related FDA issues associated with the recall of the product. Until the product recall in February 2013, final OMONTYS drug product was manufactured as a buffered aqueous solution for intravenous or subcutaneous administration. Under its collaboration with Takeda, Company was responsible, through its contract manufacturing organizations, or CMOs, for the manufacture and supply of all quantities of OMONTYS active pharmaceutical ingredient, or API, to be used in development and commercialization around the world, and Takeda was responsible for final drug product manufacture and control. In the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK